Cardiovascular benefits of oral GLP-1RA, stagnation in HbA1c target achievement, and a paradigm shift in basal insulin therapy
In this Day 3 edition of the EASD e-Learning Newsflash, SOUL Steering Committee member Rodica Pop-Busui outlines the safety outcomes and further risk reductions observed in the latest cardiovascular outcome trial. Kamlesh Khunti shares new data of a systematic review on risk factor target achievements, with surprising results: There has been no change in improvements in HbA1c targets in Europe and the US over the past 20 years, explaining the implications he draws from the findings. EASD President Chantal Mathieu gives an overview of the now-completed QWINT trial programme with once-weekly basal insulin efsitora, presenting key findings from the recently published QWINT-1 outcomes. Mathieu then highlights this year’s Banting Lecture by Steven Kahn on the central role of the beta cell in type 2 diabetes.